Oncology News | pharmaphorum

News

The FDA has started a priority review of Bristol Myers Squibb's Opdivo and Yervoy as first-line therapy for MSI-H/dMMR colorectal cancer.

News

NICE backs NHS use of Amgen's Blincyto for the consolidation phase of treatment for some patients with acute lymphoblastic leukaemia.

News

A proposed merger of the UK's Poolbeg with Austrian biotech Hookipa has been called off after the latter abruptly withdrew from negotiations.

News

Around 600 people with various types of B-cell lymphoma will be eligible for treatment with BMS' CAR-T therapy Breyanzi under new NICE guidance.

News

Boehringer Ingelheim's oral HER2 inhibitor zongertinib has started an FDA review as a lung cancer treatment with a decision due in the third quarter.

News

Bristol Myers Squibb has reported disappointing results for its checkpoint inhibitor combination Opdualag in an adjuvant melanoma study.